Ignite Creation Date:
2025-12-24 @ 10:02 PM
Ignite Modification Date:
2025-12-25 @ 7:39 PM
Study NCT ID:
NCT04869735
Status:
UNKNOWN
Last Update Posted:
2021-07-06
First Post:
2021-04-27
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Impact of Information About Booster Vaccination Against DTPolio at 25 Years on This Booster Vaccination's Realization
Sponsor:
Université de Reims Champagne-Ardenne
Organization:
Study Overview
Official Title:
Impact of Information About Booster Vaccination Against DTPolio at 25 Years on This Booster Vaccination's Realization
Status:
UNKNOWN
Status Verified Date:
2021-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Info-Vac
Brief Summary:
The aim of vaccination is to protect the patient against disease by stimulating his immune system. DTPolio is a tetravalent vaccine providing protection against pertussis, diphtheria, tetanus and polio.
In France, the vaccination schedule sets the vaccination recommendations applicable to people according to their age. In this schedule, a booster of DTPolio at the age of 25 is recommended.
The vaccination coverage for patients over 16 years of age is insufficient in France.
In France, the vaccination schedule sets the vaccination recommendations applicable to people according to their age. In this schedule, a booster of DTPolio at the age of 25 is recommended.
The vaccination coverage for patients over 16 years of age is insufficient in France.
Detailed Description:
The aim of the study is to evaluate impact of information about booster vaccination against DTPolio at 25 years on this booster vaccination's realization.
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: